TaperCommunityTaperCommunity
Forums/Drug Profiles/

Tegretol Tapering Guide

carbamazepine

Mood StabilizerFDA 1968
Go to Community Forum

Boxed Warning

Serious dermatologic reactions (Stevens-Johnson syndrome / TEN) — especially in HLA-B*1502 positive individuals. Aplastic anemia and agranulocytosis.

Overview

Carbamazepine is an anticonvulsant used for bipolar (especially mania), epilepsy, and trigeminal neuralgia. Notable for autoinduction of its own metabolism and a black-box warning for serious skin reactions in HLA-B*1502-positive individuals.

Common Doses

100mg, 200mg tablets; 100mg/5mL suspension; 100mg, 200mg, 400mg ER

Formulations

Tablets: 200mg; Chewable tablets: 100mg; Suspension: 100mg/5mL; ER tablets: 100mg, 200mg, 400mg; ER capsules: 100mg, 200mg, 300mg

Pregnancy

Category D

Mechanism of Action

Voltage-gated sodium channel blocker; decreases neuronal excitability.

Taper Notes

Slow taper over weeks. Watch for return of induced enzyme drug interactions as carbamazepine clears.

Hyperbolic Tapering Guidance

Carbamazepine's enzyme induction means many concurrent drugs will need dose review during the taper as their metabolism slows.

Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.

Withdrawal Timeline

Onset

3-7 days after stopping

📈Peak Severity

1-2 weeks

📉Resolution

4-8 weeks

⚠️Protracted Risk

Mood instability can persist months without alternative coverage

Common Withdrawal Symptoms

rebound seizures (in seizure patients)mood instabilityanxietyinsomniaGI upset

Interactions & Safety

Drug Interactions

  • CYP3A4 substrates (oral contraceptives, warfarin, many psychotropics) — markedly reduced
  • CYP3A4 inhibitors (erythromycin, fluconazole, grapefruit) — increase carbamazepine levels
  • Lamotrigine — carbamazepine reduces lamotrigine levels

Contraindications

  • Bone marrow depression
  • Recent MAOI use
  • HLA-B*1502 positive without genotype confirmation in at-risk populations

Toxicity

Stevens-Johnson syndrome / TEN (especially HLA-B*1502 in Asian populations), aplastic anemia, agranulocytosis, hyponatremia (SIADH), hepatotoxicity, dizziness, ataxia, diplopia.

Pharmacokinetics

ADME Profile

Metabolism

Hepatic via CYP3A4 (major). Potent inducer of CYP3A4, CYP1A2, CYP2C9, UGT — induces own metabolism over the first weeks.

Protein Binding

~76%

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles

Sources & References

Tegretol (carbamazepine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Regulatory sources

Official prescribing information and safety notices.

Clinical guidelines

Evidence-based deprescribing and prescribing standards.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.